- Company
- Jaqbo’s substance patent extended to 2040
- by Kim, Jin-Gu Aug 8, 2025 06:03am
- Onconic Therapeutics announced on the 7th that the patent term for Jaqbo (zastaprazan), a new drug for gastroesophageal reflux disease in the P-CAB (potassium-competitive acid blocker class, has been extended by four years and two months. According to the company, the Korean Intellectual Property Office recently extended the patent term o
- Policy
- Will RSV vaccines be included in the NIP?
- by Whang, byung-woo Aug 8, 2025 06:03am
- With the RSV (respiratory syncytial virus) vaccine being released in Korea this year, interest in its inclusion in the National Immunization Program (NIP) has been gaining attention. According to the National Assembly's legislative information system, on the 6th, Rep. Yong-ki Jeon of the Democratic Party of Korea introduced a bill titled “Pa
- Company
- Rapid growth in RSV prevention market for infants
- by Whang, byung-woo Aug 8, 2025 06:02am
- After the COVID-19 pandemic, the importance of preventing infectious diseases has been re-emphasized. A new anti-RSV (Respiratory Syncytial Virus) antibody injection for infants, Beyfortus, is gaining attention as a potential turning point in the vaccine market Korea. Attention has been focused on whether a presidential pledge to support thi
- Company
- Immunosuppressant market rapidly expands in 3yrs in KOR
- by Kim, Jin-Gu Aug 8, 2025 06:02am
- The market for major immunosuppressants such as tacrolimus, cyclosporine, and mycophenolate has rapidly expanded over the past three years. The related market grew relatively slowly at less than 5% until 2022, but since 2023, it has expanded by more than 10% a year, showing a sharp growth trend. The tacrolimus and mycophenolate markets also s
- Company
- Mounjaro set for launch in Korea this month
- by Son, Hyung Min Aug 8, 2025 06:02am
- Eli Lilly Korea's diabetes and obesity treatment, Mounjaro, is set to launch in mid-August. Therefore, it will compete against Novo Nordisk's Wegovy. Lilly plans to handle Mounjaro's distribution directly, a strategy that differentiates it from Novo Nordisk, which is currently seeking co-promotion partners. According to the distribution indus
- Company
- Donepezil ↑8%, memantine 10%↑…replaces choline alfoscerat
- by Kim, Jin-Gu Aug 7, 2025 06:10am
- Sales of donepezil, memantine, and nicergoline-based dementia treatments, which have emerged as alternatives to choline alfoscerate formulations, are growing. In the first half of this year, donepezil’s sales recorded KRW 162.6 billion, an 8% increase from the previous year. Sales of memantine-based formulation increased by 10% year-on
- Company
- Yuhan’s Leclaza to receive ₩100B in milestone payment
- by Chon, Seung-Hyun Aug 7, 2025 06:06am
- With Yuhan Corp’s new anticancer drug Leclaza approved in China, the company announced that it will receive KRW 63 billion in technology fees. Added to the technology fees secured at the end of last year for the drug’s approval in Europe, over KRW 100 billion in additional milestone payments are expected to be paid to the company. As a result,
- Policy
- Gov’t sets criteria for drug shortage prevention
- by Lee, Hye-Kyung Aug 7, 2025 06:06am
- The government will improve the criteria to raise the prices of drugs essential for patient treatment. Specifically, it will establish detailed evaluation criteria for price adjustment requests submitted by pharmaceutical companies that deem the current insurance price ceiling unreasonable. Prime Minister Min-seok Kim chaired the 7th Bioh
- Policy
- H1 Pharma exports amounted to $5.38B
- by Lee, Hye-Kyung Aug 7, 2025 06:05am
- In the first half of this year, healthcare industry exports increased by 13.2% compared to the same period last year, reaching $13.79 billion, an all-time high for a half-year period. By sector, exports were led by cosmetics at $5.51 billion (+14.9%), pharmaceuticals at $5.38 billion (+20.5%), and medical devices at $2.91 billion (△0.6%).
- Company
- 'Brintellix', stable position in antidepressant drugs mkt
- by Eo, Yun-Ho Aug 7, 2025 06:05am
- 'Brintellix' has established a stable presence in the antidepressant drugs market over the past 10 years. Its presence has not been disturbed by issues such as generic entries. According to industry sources, Lundbeck Korea's Brintellix (vortioxetine) has been growing in the market for antidepressant drugs for the past 10 years. In Q1 2012
